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Purpose: The purpose of this study was to compare the efficacy, complications, and costs associated with low-dose (<2
mg/h) alteplase (tissue plasminogen activator [t-PA]) versus urokinase for the catheter-directed treatment of acute
peripheral arterial occlusive disease (PAO) and deep vein thrombosis (DVT).
Materials and methods: A retrospective review was performed during sequential time periods on two groups with involved
extremities treated with either t-PA with subtherapeutic heparin (TPA group) or urokinase with full heparin (UK group)
at a single center. Treatment group characteristics, success rates, complications, dosages, infusion time, and costs were
compared.
Results: Eighty-nine patients with 93 involved limbs underwent treatment (54 with DVT, 39 with PAO). The treatment
groups were statistically identical (TPA: 45 limbs; 24 with DVT, 53.3%; 21 with PAO, 46.7%; UK: 48 limbs; 30 with
DVT, 62.5%; 18 with PAO, 37.5%). The overall average hourly infused dose, total dose, infusion time, success rates, and
cost of thrombolytic agent were as follows ( standard deviation): TPA, 0.86 0.50 mg/h, 21.2 15.1 mg, 24.6 11.2
hours, 89.4%, $466  $331; and UK, 13.5  5.6 (104) U/h, 4.485  2.394 million U, 33.3  13.3 hours, 85.7%,
$6871 $3667, respectively. Major and minor complication rates were: TPA, 2.2% and 8.9%; and UK, 2.1% and 10.4%,
respectively. No statistical differences in success rates or complications were observed; however, t-PA was significantly
(P < .05) less expensive and faster than urokinase.
Conclusion: Low-dose t-PA combined with subtherapeutic heparin is equally efficacious and safe compared with
urokinase. Infusions with t-PA were significantly shorter and less expensive than those with urokinase. (J Vasc Surg
2003;37:512-7.)
Although surgical intervention has been the historic
standard of care for treatment of acute peripheral arterial
occlusive (PAO) disease, catheter-directed thrombolysis
has been useful in the rapid removal of large clot burdens,
the unmasking of underlying lesions, and the simplification
of subsequent percutaneous or surgical treatments.1-3 Sim-
ilarly, thrombolysis has emerged as an alternative to antico-
agulation therapy for management of extensive symptom-
atic deep vein thrombosis (DVT) of the upper and lower
extremities.4,5 Urokinase (Abbokinase, Abbott Laborato-
ries, Chicago, Ill), a second-generation plasminogen acti-
vator, has been the dominant thrombolytic agent of choice
for catheter-directed therapy for the past 20 years on the
basis of its consistency and predictability. However, the US
Food and Drug Administration suspended the distribution
of Abbokinase in the United States in late 1998 because of
the theoretic and remote risk of viral disease transmission
arising from harvested human neonatal kidney cells.6 The
unavailability of urokinase has forced practitioners to search
for suitable alternative agents.
Alteplase (tissue plasminogen activator [t-PA]; Acti-
vase, Genentech, Inc, San Francisco, Calif), a recombi-
nantly derived analog of human t-PA, has become the
predominant replacement in the United States for catheter-
directed therapy, thrombolysis of occluded dialysis grafts,
and management of thrombosed central venous access
devices. Because of the need for thrombolysis protocols
with recombinant agents, an Advisory Panel to the Society
of Cardiovascular and Interventional Radiology published
guidelines recommending use of “low-dose” (2 mg/h)
alteplase and subtherapeutic heparin for catheter-directed
treatment of PAO and DVT on the basis of the clinical
experience of the Panel members.7 Recently, Ouriel et al8
reported significantly higher bleeding rates when compar-
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ing alteplase (22.2%) with urokinase (12.4%), but the doses
of alteplase (0.05 to 0.1 mg/kg/h) and anticoagulation
regimens used significantly exceeded the safety guidelines
recommended by the Advisory Panel. Unfortunately, no
peer-reviewed data exist comparing “low-dose” alteplase
infusions with established urokinase protocols, and many
questions remain in regards to the risks associated with
alteplase. The purpose of this study was to report the safety,
efficacy, and pharmacoeconomics of alteplase compared
with urokinase from a single center.
MATERIALS AND METHODS
Inclusion criteria for this retrospective analysis were
acute (14 days) limb ischemia (International Society for
Cardiovascular Surgery/Society for Vascular Surgery clas-
sification I-3 or II) or acute (30 days) symptomatic DVT
of the limb in patients who underwent catheter-directed
therapy with urokinase or alteplase.9 Informed consent was
obtained for all patients before therapy. Before December
1998, urokinase was the exclusive thrombolytic agent used
at our institution. Alteplase was used from December 1998
to June 2000. However, during the transition period, four
patients (eight extremities) received urokinase during the
initial therapeutic encounter and alteplase on a subsequent
separate encounter. Urokinase data were collected from
consecutive patients from October 1997 to February 1999
to ensure that the most recent protocols were being used.
Alteplase data were collected in consecutive patients from
December 1998 through June 2000.
Interventional procedures were performed in a dedi-
cated angiography suite by full-time, subspecialty board-
certified vascular interventional radiologists, each with a
minimum experience of 100 cases of catheter-directed ther-
apy. Vascular access was obtained with a 21-G micropunc-
ture set (Cook, Inc, Bloomington, Ind) and single wall
arterial entry, whenever possible. For patients with exten-
sive vascular disease and pulses that were difficult to palpate,
ultrasound scan–guided assistance was used (Site Rite,
Dymax/Bard Vascular Access, Salt Lake City, Utah). An
intrathrombic multislit infusion system (5F Unifuse, An-
gioDynamics, Glen Falls, NY) was placed for continuous
overnight infusion of either drug with endovascular tech-
niques described previously.4,10 No bolus, prelacing, pulse-
spray, or mechanical thrombectomy was performed. All
patients were observed overnight in a coronary step-down
unit where the staff was specifically trained to monitor for
bleeding complications and follow coagulation parameters.
The patients returned to the angiography suite the next
morning. The protocol for angiographic follow-up was the
same for both the alteplase and urokinase groups.
The initial hourly infused dose of either urokinase or
t-PA was decided by the interventional radiologist in con-
sideration of the clinical background and general condition
of the patient. For all patients, the fibrinogen values were
monitored at 6-hour to 8-hour intervals and the thrombo-
lytic doses titrated to maintain the fibrinogen above 100
mg/dL; however, the individual fibrinogen data were not
retrospectively collected for analysis. Termination of the
lytic infusion was based on the results of the follow-up
angiogram. If the angiogram showed complete lysis, the
infusion was terminated; for partial lysis, the infusion was
continued for another 6 to 24 hours after repositioning of
the catheter system; and if no lysis was seen, the procedure
was either terminated and considered a technical failure or
given another 6 to 24 hours of lytic therapy at the discretion
of the interventional radiologist.
For the urokinase treatment group, 500,000 U of
urokinase (Abbokinase) were diluted in 500 mL of normal
saline solution and infused at approximately 120,000 IU/h
(range, 50,000 to 240,000 U/h, 120 to 240 mL/h).
Patients underwent anticoagulation therapy with unfrac-
tionated heparin to maintain the partial thromboplastin
time at 1.5 to two times the baseline. Heparin was admin-
istered either through a peripheral intravenous line or
through the outer sheath. For the t-PA treatment group,
t-PA (Activase) was kept reconstituted (1 mg/mL) and
frozen (20° C) in 2-mg sterile glass vials.11 Before the
initiation of thrombolytic therapy, t-PA vials were thawed
and immediately diluted in normal saline solution to a final
concentration of usually 0.02 mg/mL for infusion (range,
0.01 to 0.02 mg/mL, 25 to 50 mL/h; Genentech, Inc,
unpublished data). Dosing of alteplase was based on the
recommendations of the Advisory Panel to the Society for
Cardiovascular and Interventional Radiology on Throm-
bolytic Therapy.7 Alteplase was infused with a non–weight-
based regimen at the typical rate of 0.5 mg/h for PAO and
1.0 mg/h for DVT (range, 0.25 to 2.0 mg/h). Subthera-
peutic heparin was administered through the outer sheath
to maintain the partial thromboplastin time at less than 1.5
times the baseline.
Outcome variables. Outcome variables included ini-
tial and total drug doses, infusion time, success rates, com-
plications, and estimated drug costs. Thrombolysis was
defined as complete (5% residual clot), partial, or failure
(no angiographic evidence of lysis). Successful thromboly-
sis was defined as complete or partial lysis with: 1, PAO,
improvement of the International Society for Cardiovascu-
lar Surgery/Society for Vascular Surgery scale by one or
more classifications; or 2, DVT, resolution of the acute pain
and edema of the extremity after intervention. Major com-
plications were defined as death, intracranial hemorrhage,
bleeding requiring transfusion or surgery, or increase in
length of hospital stay. Minor complications were defined
as adverse events requiring only conservative therapy, such
as small access site hematomas. Analysis of estimated drug
costs were based on the list price for urokinase in 1998
($383/250,000 IU vial) or alteplase in 1999, which had
been reconstituted, aliquotted in 2-mg vials, and frozen
($22/mg). The treatment group characteristics, infusion
time, success rates, complications, and estimated drug costs
were compared with the Student t test for continuous data
and 2 analysis for dichotomous data. The predictors of
thrombolytic complications associated with each drug were
analyzed with multivariable logistic regression analysis. A P
value of less than .05 was considered to be statistically
significant.
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RESULTS
Patient baseline characteristics. Eighty-nine pa-
tients (43 men, 46 women; mean [ standard deviation]
age, 52.4  19.3 years) with 93 involved extremities un-
derwent treatment with catheter-directed thrombolysis.
The gender, age, disease type, and anatomic location were
not statistically different for extremities treated with t-PA
(TPA group) or urokinase (UK group; Table I).
Details of thrombolysis. The infusion times overall
(PAO and DVT) and for each disease group (PAO or DVT)
were significantly shorter in the TPA group compared with
the UK group (P .05; Table II). Similarly, the drug costs
overall and for each disease group were significantly less
expensive in the TPA group compared with the UK group
(P  .0001).
The average overall hourly infusion dose, total dose,
infusion time, and estimated drug costs (respectively) for
t-PA versus urokinase were: TPA, 0.86  0.50 mg/h,
21.2  15.1 mg, 24.6  11.0 hours, and $466  $331;
and UK, 13.5  5.6 (104) U/h, 4.485  2.394 (106) U,
33.3  13.3 hours, and $6871  $3667.
Success and complication rates. Results of throm-
bolysis were not statistically different for each treatment
group (Table III). The percentages of thrombolytic success
(complete and partial) overall and for each disease group,
respectively, were: TPA, 88.9%, 87.5% for DVT, and 90.5%
for PAO; UK, 85.4%, 83.4% for DVT, and 88.9% for PAO.
No statistical differences were seen in major or minor
bleeding between the two groups (Table III). Both groups
had one major complication. One patient receiving t-PA
(2.2%) had spontaneous lower gastrointestinal bleeding
(melena) and underwent conservative treatment with 2
units of packed red blood cells. One patient receiving
urokinase (2.1%) had a large access site hematoma and
underwent treatment with 2 units of packed red blood cells.
There were no deaths, intracranial hemorrhage, need for
intensive care unit monitoring, or surgical interventions in
either group. Four patients treated with t-PA (8.9%) and
five with urokinase (10.4%) had minor bleeding events. All
nine patients had access site–related hematomas; however,
no intensive care unit monitoring, operative repair, or
blood transfusions were required. There were no observed
signs of systemic fibrinolysis (eg, gingival bleeding, bleed-
ing from the oral mucosa, epistaxis, or subcutaneous ecchy-
moses [purpura thrombolyticus]) in either treatment
group.12
Multivariable logistic regression analysis of compli-
cations. Univariate and multivariate analysis of variables
affecting complications showed no statistically significant
predictors of adverse outcomes (Table IV). Age, gender,
disease type, location, hourly infusion rate, total drug dose,
and total infusion time were nonpredictive in this study.
DISCUSSION
For the past two decades, urokinase has been the dom-
inant and virtually exclusive agent used for peripheral
thrombolytic therapy in the United States. Dotter, Rosch,
and Seaman13 first showed that intrathrombic delivery of
streptokinase, a first-generation agent, was far more effi-
cient in lysing arterial thrombus than systemic intravenous
infusion. Subsequent studies with the second generation
agent, urokinase, with improved fibrin specificity, showed a
more efficacious and improved safety profile compared with
streptokinase.14,15 Urokinase rapidly gained favor because
of its consistency, predictability, and lack of antigenic com-
plications. Despite the availability of recombinant t-PA, few
investigators explored the peripheral use of t-PA in the
United States.16,17 Urokinase remained the exclusive agent
because the general prevailing opinion was that t-PA was
vastly more expensive and far more prone to hemorrhagic
complications compared with urokinase ($1100 vial Acti-
vase compared with $383 vial of Abbokinase) despite the
lack of formal large-scale comparative clinical trials. In
1999, the US Food and Drug Administration abruptly
suspended the distribution of Abbokinase because of pos-
sible viral contamination of bulk tissue before processing.18
Abbokinase is derived from kidney cell tissue culture from
neonatal renal tissue procured in Colombia, South Amer-
ica. The impact of the shortage was felt immediately; most
American and Canadian practitioners had no prior experi-
ence with t-PA as an alternative, and optimal doses were not
understood. Early studies with t-PA reported excessive
major bleeding complications (22% to 33%).8,19 Because of
the need for safe practice guidelines, the Society of Cardio-
vascular and Interventional Radiology assembled a multi-
disciplinary Advisory Panel to formulate recommendations
on alternatives to urokinase.7 The Panel recommended that
t-PA should be dosed 2 mg/h or less (median range, 0.5 to
1.0 mg/h) with low-dose heparin. The purpose of this
study was to compare the safety, efficacy, and costs of t-PA
infusions with the Advisory Panel guidelines compared
with our prior established experience with urokinase.
With the Advisory Panel guidelines, alteplase was
equally efficacious as urokinase for acute arterial thrombosis
but required shorter infusion times (P  .0009). The
Table I. Baseline characteristics of 96 treated extremities
in 89 patients
t-PA UK P value
Gender
Male 22 (48.9%) 22 (45.8%) .77
Female 23 (51.1%) 26 (54.2%) .77
Age (years  standard deviation)
Overall 52.2  19.6 53.6  19.2 .72
DVT 43.5  17.6 46.0  17.5 .60
PAO 62.2  17.2 66.4  15.0 .43
Disease/location
DVT (n  54) 24 (44.4%) 30 (55.6%) .37
Upper extremity
(n  22)
12 (54.5%) 10 (45.5%) .22
Lower extremity
(n  32)
12 (37.5%) 20 (62.5%) .22
PAO (n  39) 21 (53.8%) 18 (46.2%) .37
Native artery (n  23) 10 (43.5%) 13 (56.5%) .12
Bypass graft (n  16) 11 (68.8%) 5 (31.3%) .12
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overall complete/partial lysis rate (90.5% t-PA, 83.3%
urokinase; P  .7) was consistent with results of other
studies comparing t-PA with urokinase for PAO.20,21
Graor, Olin, and Bacharach20 reported the results of a
randomized prospective pilot trial comparing t-PA (0.05
mg/kg/h  24 hours) versus urokinase (240,000 U/h)
for treatment of acute limb ischemia in 45 patients and
reported a success rate of 91% with t-PA and 86% with
urokinase with a faster time to reperfusion with t-PA. The
STILE (Surgery versus Thrombolysis for Ischemia of the
Lower Extremity) study was a formal large-scale compara-
tive clinical trial that compared surgical revascularization
versus thrombolysis for the management of acute and
chronic limb ischemia. The thrombolysis arm was further
randomized to urokinase (n 112; 250,000 U bolus, then
240,000 U/h  4 hours, then 120,000 U/h  36 hours)
or t-PA (n  137; 0.1 mg/kg/hr  12 hours, then
decreased to 0.05 mg/kg/h  12 hours during the trial).
No statistical differences were seen in outcome or compli-
cations between the t-PA or urokinase groups. Our results
indicate that a high rate of efficacy can be achieved at far
lower doses (0.76  0.5 mg t-PA) compared with prior
reports that used weight-adjusted doses equivalent to 4 to 8
mg/h in an 80-kg patient.16,20 The overall t-PA doses in
our study averaged 19.0 mg/patient, which is nearly 2.5-
fold to five-fold lower a dose compared with the Graor,
Olin, and Bacharach20 or STILE trials.21
The results of venous thrombolysis with t-PA (87.5%
complete/partial lysis) were consistent with previously re-
ported small series22-25 and appeared equally efficacious
and safe compared with our prior experience with uroki-
nase,5 except for a requirement for significantly shorter
infusion times. The only comparative study evaluating t-PA
versus urokinase for DVT was a randomized prospective
trial involving 69 patients.26 Patients with acute DVT were
randomized to one of three treatment groups: heparin
alone, catheter-directed t-PA (5 mg/h  4 hours), or
urokinase (100,000 U/h  7 days). The urokinase group
showed 50% lysis compared with 27% for the t-PA group.
At 1-year follow-up, the urokinase group showed fewer
postthrombotic complications compared with the t-PA or
heparin group, but arguably, the outcomes may be more a
manifestation of thrombolytic technique than inherent dif-
ferences in the molecules.
Major and minor adverse bleeding complications were
equivalent in both treatment groups. With low-dose alte-
plase as an alternative to urokinase, we could not support
the earlier observations that t-PA has a higher rate of
adverse bleeding compared with urokinase. The discrep-
ancy between our data and prior reports may be attribut-
able to: 1, lower hourly infused doses of t-PA; 2, lower
overall doses; 3, implementation of low-dose heparin regi-
mens; and 4, dedicated full-time interventional radiologists
Table III. Outcomes of thrombolytic therapy
t-PA UK P value
Thrombolytic success
Overall (DVT and PAO)
Complete 27 (60.0%) 26 (54.2%) .57
Partial 13 (28.9%) 15 (31.2%) .80
None 5 (11.1%) 7 (14.6%) .62
Complete/partial 40 (88.9%) 41 (85.4%) .40
DVT
Complete 14 (58.3%) 14 (46.7%) .39
Partial 7 (29.2%) 11 (36.7%) .56
None 3 (12.5%) 5 (16.6%) .67
Complete/partial 21 (87.5%) 25 (83.3%) .69
PAO
Complete 13 (61.9%) 12 (66.7%) .76
Partial 6 (28.6%) 4 (22.2%) .65
None 2 (9.5%) 2 (11.1%) .87
Complete/partial 19 (90.5%) 16 (88.9%) .90
Complications
Major 1 (2.2%) 1 (2.1%) .96
Minor:overall 4 (8.9%) 5 (10.4%) .80
DVT 2 (4.4%) 2 (4.2%) .82
PAO 2 (4.4%) 3 (6.3%) .51
Table II. Details of thrombolytic infusion
t-PA UK P value
Hourly infused dose ( standard deviation)
Overall 0.86  0.50 mg/h 13.5  5.6 104 U/h
DVT 0.96  0.54 mg/h 15.0  6.3 104 U/h
PAO 0.76  0.46 mg/h 11.0  2.8 104 U/h
Total drug dose ( standard deviation)
Overall 21.2  15.1 mg 4.485  2.394 million U
DVT 23.2  15.1 mg 4.836  2.662 million U
PAO 19.0  15.2 mg 3.938  1.849 million U
Infusion time (h  standard deviation)
Overall 24.6  11.0 33.3  13.3 .0009
DVT 24.1  10.6 33.4  14.2 .0110
PAO 25.1  11.6 32.3  12.0 .0390
Drug costs ($)
Overall 466  331 6871  3667 .0001
DVT 511  331 7408  4078 .0001
PAO 418  334 6032  2833 .0001
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with extensive experience in catheter-directed therapy.8,19
One of these studies19 did included a full-time interven-
tional radiologist, although it was early in the t-PA experi-
ence. In a metaanalysis of 12 studies involving 1291 pa-
tients undergoing catheter-directed therapy with t-PA, the
overall incidence rate of major adverse bleeding was 5.1%
(range, 0 to 17%) with t-PA,27 similar to the reported
experience with urokinase.2,21,28,29 A recent Cleveland
Clinic registry of 653 consecutive patients treated with
urokinase or t-PA showed significantly higher major bleed-
ing (22.2%) and intracranial hemorrhage (2.8%) rates in the
t-PA treatment group.8 However, analysis of the t-PA
treatment group showed significantly larger hourly (0.05 to
0.1 mg/kg/h  24 hours, full heparin) and overall doses
than our series—doses that were nearly 500% to 900%
higher. No intracranial bleeding was experienced in our
experience in either treatment group. Minor adverse bleed-
ing rates of t-PA and urokinase were 8.9% and 10.4%,
respectively.
Variables associated with adverse bleeding remain con-
troversial. Thomas and Gaines30 investigated factors asso-
ciated with an increased risk of complications during
thrombolysis with univariate and multivariate analysis of
798 patients in a British thrombolytic registry database,
most of whom were treated with t-PA in doses ranging
from 0.5 to 5 mg/h. Case selection appeared to be the
most important factor influencing the occurrence of com-
plications, and radiologic technique, such as agent used,
sheath size, length of lysis, dose of lysis, use of heparin or
adjunctive procedures, had no relationship to the rate of
complications. Univariate and multivariate analysis of our
patients did not reveal positive predictors of adverse events,
presumably because of the small data sets for both treat-
ment groups.
Pharmacoeconomic analysis showed significant cost
savings with t-PA compared with urokinase. T-PA was
nearly 15 times less expensive than urokinase overall. For
every 100 patients treated, the use of t-PA would save our
institution approximately $600,000. Even considering the
costs associated with aliquotting and freezing t-PA into
2-mg vials, the cost savings remain substantial.
The interpretations of this study are limited by it being
a small, retrospective, nonrandomized analysis from a sin-
gle center. Moreover, it is possible that because this was a
sequential comparison between urokinase and t-PA, our
results favor t-PA as interventional techniques have im-
proved with time. However, favorable outcomes of this
preliminary study suggest that low-dose t-PA, when follow-
ing the Advisory Panel guidelines, is equally efficacious and
safe compared with traditional urokinase regimens, with a
shorter duration of thrombolysis and significant cost sav-
ings overall. Confirmation of these findings is warranted on
a large, randomized, prospective, multicenter basis.
We thank Mr Eric Huffman for administrative assis-
tance in the preparation of this manuscript.
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